title: The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi's sarcoma.
abstract: A combination of highly active antiretroviral therapy (HAART) and liposomal anthracycline chemotherapy is the standard of care for advanced HIV-associated Kaposi's sarcoma, despite concerns that the chemotherapy may adversely affect lymphocyte subsets and HIV viraemia. We showed in 50 patients that liposomal anthracyclines used with HAART did not lead to a significant loss of CD4 or CD8 cells or an increase in HIV-1 viral load during or up to 12 months after chemotherapy.
authors.affiliation: Department of Oncology, Chelsea and Westminster Hospital, London, UK.
authors.forename: Ben
authors.initials: B
authors.lastname: Esdaile
authors.forename: Matt
authors.initials: M
authors.lastname: Davis
authors.forename: Simon
authors.initials: S
authors.lastname: Portsmouth
authors.forename: Debashis
authors.initials: D
authors.lastname: Sarker
authors.forename: Mark
authors.initials: M
authors.lastname: Nelson
authors.forename: Brian
authors.initials: B
authors.lastname: Gazzard
authors.forename: Mark
authors.initials: M
authors.lastname: Bower
mesh_terms: D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications* / Q000276:immunology / Q000821:virology; D015497:HIV-1; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D016176:T-Lymphocyte Subsets / Q000187:drug effects; D019562:Viral Load
chemical_list: D000903:Antibiotics, Antineoplastic; D008081:Liposomes